Alemtuzumab Injection ( DrugBank: Alemtuzumab )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	2

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04082260 (ClinicalTrials.gov)	January 2017	28/8/2019	Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response	Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response	Multiple Sclerosis	Drug: Alemtuzumab Injection [Lemtrada]	University Hospital Muenster	NULL	Recruiting	18 Years	N/A	All	150		Germany
2	NCT04633967 (ClinicalTrials.gov)	May 15, 2016	26/10/2020	Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.	Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.	Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis	Drug: Alemtuzumab Injection	Maritime Neurology	NULL	Active, not recruiting	18 Years	65 Years	All	30		Canada